Document ID: chunk:federal_register_of_legislation:F2022C00926:front:0:p4
Version: federal_register_of_legislation:F2022C00926
Segment Type: other
Provision Reference: 
Character Range: 8556–11571

of therapeutic radiation for cancer, where the region of the affected eye was in the field of radiation, at the time of the clinical onset of conjunctivitis;
(17)      having a benign or malignant neoplasm affecting the conjunctiva or eyelid margin of the affected eye at the time of the clinical onset of conjunctivitis;
(18)      being in an immunocompromised state as specified at the time of the clinical onset of conjunctivitis;
            Note: immunocompromised state as specified is defined in the Schedule 1 - Dictionary.
(19)      having blepharitis of the affected eye at the time of the clinical worsening of conjunctivitis;
(20)      having an infection of the conjunctiva of the affected eye at the time of the clinical worsening of conjunctivitis;
            Note: infection of the conjunctiva is defined in the Schedule 1 - Dictionary.
(21)      having a condition of the affected eye from the specified list of conditions at the time of the clinical worsening of conjunctivitis;
            Note: specified list of conditions is defined in the Schedule 1 - Dictionary.
(22)      having a condition that causes chronic lack of sufficient lubrication and moisture on the surface of the affected eye at the time of the clinical worsening of conjunctivitis;
Note: Examples of conditions associated with a chronic lack of sufficient lubrication and moisture on the surface of the eye include dysfunctional tear syndrome, keratoconjunctivitis sicca and Sjögren syndrome.
(23)      having ocular or periocular exposure to an allergen within the 24 hours before the clinical worsening of conjunctivitis;
            Note: allergen is defined in the Schedule 1 - Dictionary.
(24)      having an autoimmune disease at the time of the clinical worsening of conjunctivitis;
(25)      having graft versus host disease at the time of the clinical worsening of conjunctivitis;
(26)      having diabetes mellitus at the time of the clinical worsening of conjunctivitis;
(27)      having topical medication applied to the affected eye within the 48 hours before the clinical worsening of conjunctivitis;
(28)      taking a drug from the specified list of drugs for at least the seven days before the clinical worsening of conjunctivitis;
            Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(29)      taking a drug which is associated in the individual with:
(a)          the worsening of conjunctivitis during drug therapy; and
(b)          the improvement of conjunctivitis within seven days of discontinuing or tapering drug therapy;
         where treatment with the drug continued for at least the seven days before the clinical worsening of conjunctivitis;
(30)      having ocular or periocular exposure to an irritant substance within the 24 hours before the clinical worsening of conjunctivitis;
            Note: irritant substance is defined in the Schedule 1 - Dictionary.
(31)      having mustard gas exposure to the affected eye within the 24 hours before the clinical